CLINICAL TRIALS PROFILE FOR APTIVUS

All Clinical Trials for APTIVUS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00146328 ↗	Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects	Completed	Boehringer Ingelheim	Phase 2/Phase 3	2001-04-01	The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg ritonavir BID) when administered with other antiretroviral medications.
NCT00344123 ↗	Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects	Completed	Boehringer Ingelheim	Phase 1	2007-02-01	Tipranavir (TPV) plus ritonavir (RTV) is indicated for use as part of an antiretroviral treatment regimen for resistant HIV-1 infection in adult patients. Since significant cholesterol and triglyceride elevations are commonly reported during TPV/RTV treatment, effective treatment strategies are critical to prevent long-term cardiovascular events. Rosuvastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitor, is unlikely to interact with TPV/RTV since it is not extensively metabolized, however, a formal drug interaction study is needed before this combination can be recommended. This study will examine the pharmacokinetic interactions between tipranavir/ritonavir (TPV/RTV [TPV/r] 500 mg/200 mg twice daily [B.I.D]) and single dose rosuvastatin when the two are co-administered to healthy adult volunteers. The investigators hypothesize that if tipranavir 500 mg is co-administered with low-dose ritonavir 200 mg and rosuvastatin (10 mg) no significant clinical interaction will occur.
NCT00344123 ↗	Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects	Completed	Johns Hopkins University	Phase 1	2007-02-01	Tipranavir (TPV) plus ritonavir (RTV) is indicated for use as part of an antiretroviral treatment regimen for resistant HIV-1 infection in adult patients. Since significant cholesterol and triglyceride elevations are commonly reported during TPV/RTV treatment, effective treatment strategies are critical to prevent long-term cardiovascular events. Rosuvastatin, a potent 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitor, is unlikely to interact with TPV/RTV since it is not extensively metabolized, however, a formal drug interaction study is needed before this combination can be recommended. This study will examine the pharmacokinetic interactions between tipranavir/ritonavir (TPV/RTV [TPV/r] 500 mg/200 mg twice daily [B.I.D]) and single dose rosuvastatin when the two are co-administered to healthy adult volunteers. The investigators hypothesize that if tipranavir 500 mg is co-administered with low-dose ritonavir 200 mg and rosuvastatin (10 mg) no significant clinical interaction will occur.
NCT00517192 ↗	Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI	Terminated	Boehringer Ingelheim	Phase 3	2007-09-01	The objective of this study is to compare the efficacy and safety of Tipranavir/ritonavir (TPV/r, 500mg/200mg twice daily) to the safety and efficacy of Darunavir/ritonavir (DRV/r 600 mg /100 mg twice daily) in combination with investigator selected optimised background regimens in patients who are three-class (Nucleoside reverse transcriptase inhibitors (NRTI), Nonnucleoside reverse transcriptase inhibitors (NNRTI), and Protease inhibitor (PI)) treatment-experienced (a minimum of 3-months duration for each class) with resistance to more than one PI on the screening virtual phenotype resistance testing.
NCT00531206 ↗	Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.	Completed	Boehringer Ingelheim		2006-08-01	This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Aptivus (tipranavir) in combination with low-dose Norvir (ritonavir) will durably suppress viral load and may achieve suppression of viral load below the limit of detection.
NCT00615290 ↗	Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy	Completed	Boehringer Ingelheim		2007-06-01	To obtain information on clinical practices for patients treated by Aptivus in real life

Clinical Trial Conditions for APTIVUS

Condition Name

Condition Name for APTIVUS
Intervention	Trials
HIV Infections	7

Condition MeSH

Condition MeSH for APTIVUS
Intervention	Trials
HIV Infections	7
Infection	1
Communicable Diseases	1
Infections	1

Clinical Trial Locations for APTIVUS

Trials by Country

Trials by Country for APTIVUS
Location	Trials
United States	39
Canada	6
Germany	3
France	3
Australia	2

Trials by US State

Trials by US State for APTIVUS
Location	Trials
Maryland	3
California	3
Florida	2
Texas	2
North Carolina	2

Clinical Trial Progress for APTIVUS

Clinical Trial Phase

Clinical Trial Phase for APTIVUS
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for APTIVUS
Clinical Trial Phase	Trials
Completed	6
Terminated	1

Clinical Trial Sponsors for APTIVUS

Sponsor Name

Sponsor Name for APTIVUS
Sponsor	Trials
Boehringer Ingelheim	6
Johns Hopkins University	1
National Institute of Mental Health (NIMH)	1

Sponsor Type

Sponsor Type for APTIVUS
Sponsor	Trials
Industry	6
Other	2
NIH	2

APTIVUS Market Analysis and Financial Projection

Last updated: April 28, 2026

Aptivus (tipranavir): what the current clinical-trials readout and market math indicate

What is Aptivus and what is its current clinical focus?

Aptivus is the brand name for tipranavir, an HIV-1 protease inhibitor (PI) with clinical use in heavily treatment-experienced adults with HIV strains resistant to available PIs, typically in combination with ritonavir boosting.

The practical reality for “clinical trials update” is that Aptivus is an established, mature product. Most activity in 2023 to 2025 is typically in:

• long-term observational cohorts and registry analyses,
• guideline-facing evidence syntheses,
• and comparative effectiveness work rather than large pivotal late-stage trials.

No new late-stage (Phase 3/registrational) readouts for Aptivus were identified in the public trial record set that is commonly used for headline updates (FDA-label aligned registrational program signals and major registrational trial registries). The current evidentiary base for Aptivus remains driven by earlier PI-experience and resistance-context data and label-required combinations.

Implication for investors and R&D teams: Aptivus is best treated as a platform for lifecycle management rather than an active late-stage development program.

Where is Aptivus on the market curve now?

Aptivus is a late-life antiretroviral in a crowded HIV PI landscape. Its commercial profile is shaped by:

• class competition (newer PIs and integrase inhibitor regimens),
• resistance and treatment-history selection (narrower use case than frontline regimens),
• and the fact that HIV treatment paradigms shifted toward integrase inhibitor-based therapy.

Key market mechanics for market size projection:

1. Demand is indication- and history-constrained

   • Tipranavir use is largely confined to patients with resistant HIV and limited options after prior PI exposure.
   • That creates a “remanufacturing” demand stream tied to progression in resistant cohorts, not to new first-line initiations.

2. Pricing and payer dynamics

   • In the mature PI segment, payers push preferential access to regimens with simpler dosing and better tolerability profiles.
   • Tipranavir’s retained role often relies on payer coverage for resistant cases.

3. Competitive switching pressure

   • Newer agents reduce the share of patients who end up in PI-only salvage scenarios.
   • That pressure typically limits long-horizon unit growth, even when the patient population exists.

What do the typical Aptivus sales drivers imply for 2025 to 2030 projection?

Because this is a mature HIV drug, the projection model is not built around unit growth from new penetrations. It is built around:

• base decline or stabilization from competitive switching,
• retention due to resistant-patient necessity,
• geography mix (public-sector procurement dynamics vs private-market uptake),
• and treatment guideline evolution affecting the size of “eligible salvage” cohorts.

A defensible forward-looking stance for Aptivus is:

• Short-term (2025-2026): flat-to-slight decline in global revenue with periodic stabilization where resistant cohort incidence and access to boosted PIs remain strong.
• Medium-term (2027-2030): continued mild decline as integrase inhibitor dominance reduces downstream salvage PI initiations.
• Downside: faster decline if payer formularies further restrict tipranavir relative to alternative boosted regimens.
• Upside: stabilization in regions where clinical practice maintains boosted PI salvage options for resistant HIV populations.

How should investors frame Aptivus’s pipeline value vs revenue value?

Aptivus has pipeline relevance mainly through:

• formulation lifecycle actions (if any),
• post-marketing evidence generation,
• and label optimization or regimen-context studies rather than brand-new drug substance development.

For market valuation, the core driver stays cash flow durability rather than R&D re-rating.

---

Clinical-trials update: what’s observable from the open record trendlines

What types of trials persist for mature antiretrovirals?

For established HIV brands like Aptivus, the ongoing clinical record commonly concentrates in:

• comparative effectiveness in real-world cohorts,
• safety and tolerability in routine practice (especially long-term),
• resistance surveillance studies,
• and regimen durability analyses rather than new efficacy-of-record pivots.

What does that mean for the “update” you can use?

In practice, you get less of:

• “new Phase 3 wins,” and more of:
• “evidence maintenance” and “outcomes confirmation.”

So the decision-useful question becomes: is Aptivus losing patients because it is clinically displaced, or because it is operationally de-prioritized? The market projection logic above assumes both pressures persist, with stabilization risk limited to pockets of high need in resistant cohorts.

---

Market analysis and projection: revenue path under mature HIV dynamics

How does the HIV treatment landscape typically affect PI brand trajectories?

Aptivus sits in the protease inhibitor segment, where:

• integrase inhibitors have shifted first-line and many salvage pathways,
• PI use increasingly concentrates in resistance-driven scenarios,
• and uptake tends to track the incidence of PI-resistant disease and clinician familiarity rather than broad regimen adoption.

Projection framework (base-case logic)

To project revenue forward for a mature PI:

• Units move with the number of eligible resistant patients and access constraints.
• Net revenue moves with pricing pressure, payer coverage, and tender processes.
• Volatility comes from formulary decisions and procurement cycles, not from clinical breakthrough events.

Base case (2025 to 2030):

• 2025-2026: modest decline or near-flat trajectory.
• 2027-2030: mild but persistent decline.

Decision-grade market outcomes to track

For Aptivus, the best leading indicators are:

• formulary access in major markets for resistant-HIV salvage,
• retention of boosted PI salvage pathways in local guidelines,
• and net price changes tied to procurement.

---

Competitive and regulatory context that drives Aptivus’s lifecycle economics

What competitive structure matters most?

The competitive set is broader than “other PIs” and includes:

• newer classes that reduce downstream PI salvage use,
• regimens that substitute boosted PI salvage with alternatives in treatment guidelines,
• and generics that intensify price pressure in mature antiretroviral segments.

What regulatory reality matters most?

Tipranavir remains used under label-defined constraints: heavily treatment-experienced patients with resistant HIV and boosted dosing context. That anchors use, but it also limits expansion.

---

Key Takeaways

• Aptivus (tipranavir) is a mature HIV protease inhibitor whose clinical-trials activity is expected to skew toward post-marketing evidence and real-world outcomes rather than registrational Phase 3 growth.
• Market demand is constrained to resistant, treatment-experienced populations, so projection is driven by competitive switching and payer/formulary access, not by broad new initiations.
• Base-case market path for 2025-2030: flat-to-mild decline, turning into mild persistent decline as integrase inhibitor dominance continues to shrink eligible salvage PI cohorts.
• Investor and R&D value is more cash-flow durability and lifecycle management than pipeline re-rating from new registrational efficacy.

---

FAQs

1. Is Aptivus still used in current HIV treatment practice?
   Yes, primarily in treatment-experienced patients with resistant HIV, under boosted PI salvage logic consistent with label constraints.

2. Does Aptivus have ongoing Phase 3 registrational trials?
   Mature-drug patterns indicate that headline registrational activity is limited; ongoing studies typically center on real-world outcomes and post-marketing evidence rather than new Phase 3 efficacy-of-record programs.

3. What most affects Aptivus revenue over the next 5 years?
   The main drivers are formulary access, net pricing, and the share of patients reaching PI-salvage rather than integrase-dominant alternatives.

4. How does competition impact Aptivus compared with earlier years?
   Competitive pressure is sustained by class shifts in HIV therapy and price competition in mature antiretroviral segments.

5. What should a monitoring dashboard for Aptivus prioritize?
   Track net price, tender/formulary status in key markets, and real-world uptake in resistant patient cohorts rather than expecting new efficacy-led demand expansion.

---

References (APA)

[1] FDA. (n.d.). Aptivus (tipranavir) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/
[2] ClinicalTrials.gov. (n.d.). Aptivus (tipranavir) studies. U.S. National Library of Medicine. https://clinicaltrials.gov/